William, good synopsis of Cerevel and comparison with Anavex. I think it is important to note that CERE is over 88% institutionally owned and advice(?) from those institutions may have had weight on the decision of the buyout since the institutions have a lot shorter expectation of ROI than other shareholders. Below is an article about J&J neuroscience acquisitions and future plans....another possible partner?
Anavex is a reverse merger, reverse split, OTC uplist to NASDAQ, it has NEVER had any investment banking support. Unlike the way many other biotech's have been "humped and pumped by Goldman and Morgan Stanley" or similar outfits.